MONDAY, SEPTEMBER 26, 2016

National Institute of Allergy and Infectious Diseases (NIAID)

5601 Fishers Lane, MSC 9806
Bethesda, MD - 20892-9806

National Institute of Allergy and Infectious Diseases (NIAID) News

NIH organizations issue report on Ebola patient's care

A new report from various organizations under the National Institutes of Health details the clinical course of a 34-year-old American with Ebola virus disease who received intensive supportive care through a clinical trial at the NIH Special Clinical Studies Unit. Read More »

Purdue team creates 3-D map of Zika virus

Purdue University researchers recently created a near-atomic level map of the Zika virus, which could spark vaccines, antiviral drugs, antibodies and a diagnostic test capable of differentiating Zika virus infections from dengue infections. Read More »

NIH commemorates World Tuberculosis Day

The National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently released a statement verifying the organization’s commitment to researching, preventing and treating tuberculosis. Read More »

Blood test predicts chances of TB development

A new study from the South African Tuberculosis Vaccine Initiative at the University of Cape Town suggests that a simple blood test can predict a person’s chances of developing tuberculosis. Read More »

Phase 3 of sarcoma chemotherapy trial is discontinued

A clinical trial designed to compare three advanced Kaposi’s sarcoma chemotherapy treatment regimens combined with antiretroviral treatment for AIDS patients will not accept any more participants into its oral chemotherapy drug etoposide tests. Read More »

All study subjects protected with experimental dengue vaccine

All of the subjects who participated in a clinical trial for an experimental dengue virus vaccine showed vastly different results, as the 21 vaccine recipients did not develop the dengue infection, but the 20 placebo recipients did contract the infection. Read More »

Dengue-fever test vaccine shows promise in early clinical trials

A team of scientists at the University of Vermont (UVM) Vaccine Testing Center has been working to develop an efficient, single-dose vaccine designed to protect people from the four strains of dengue fever, and the team said this week that clinical trials on a test vaccine have been promising so far. Read More »

NIAID's HOPE study looks at dapivirine vaginal rings to prevent HIV

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), will proceed with the HIV Open-label Prevention Extension (HOPE) Phase 3B trial to study the use of a dapivirine vaginal ring to prevent HIV in women.  Read More »

Experimental antibody shields monkeys from Ebola

Researchers from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently developed an antibody that protects monkeys from developing Ebola infections. Read More »

Experimental Ebola drug ZMapp requires further research

ZMapp, an experimental treatment for the Ebola virus, may be beneficial to Ebola patients but there is still a lack of data from its developer, Mapp Biopharmaceutical Inc., to determine whether it can be used to treat humans. Read More »

Liberian study shows experimental Ebola vaccines are immunogenic and well-tolerated

Two investigational Ebola vaccines have been tested and proved to be immunogenic and well-tolerated among 1,500 participants in a randomized, placebo-controlled clinical trial. Read More »

Vaginal ring with antiretroviral drug offers partial HIV protection

The National Institutes of Health recently conducted studies that show an antiretroviral drug within a vaginal ring may be the strongest protector for women against HIV infections. Read More »

Research shows HIV reservoirs refill through replication during treatments

Scientists from the National Institutes of Allergy and Infectious Diseases recently conducted a study demonstrating that ongoing HIV replication continues even during antiretroviral therapy (ART) treatments. Read More »

Brazil launches Phase 3 trial for dengue vaccine

Researchers from the Butantan Institute, a nonprofit manufacturer of immunobiologic solutions for Brazil, recently launched a multi-center, controlled Phase 3 trial that will examine an investigational dengue fever vaccine. Read More »

NIAID highlights accomplishments from 2015

The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, recently released a slideshow that emphasizes the notable scientific progress that NIAID researchers have accomplished for 2015. Read More »

NIH researchers create HIV prevention and treatment guidelines

National Institutes of Health (NIH) researchers at the National Institute of Allergy and Infectious Diseases (NIAID) recently used three clinical studies to create guidelines for preventing and treating HIV infections. Read More »

NIH encourages acceleration to eliminate AIDS

The National Institutes of Health (NIH) recently released statements in honor of World AIDS Day that encourage scientists to speed their efforts to eliminate AIDS as soon as possible. Read More »

NIAID researchers create blueprint for HIV prevention and treatment

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), have used evidence from three large clinical trials to develop a blueprint of prevention and treatment for HIV infections. Read More »

Research standards for HOPE Act released

The Department of Health and Human Services (HHS) recently published the research safeguards and criteria that are part of the HIV Organ Policy Equity (HOPE) Act. Read More »

NIH issues criteria for HIV-positive organ transplant research

The National Institutes of Health (NIH) issued criteria last week on research on possible organ transplants between HIV-positive patients. Read More »